As peptide drugs, such as GLP-1 receptor agonist Semaglutide become central in treatment of a range of therapeutic areas, reliable bioanalysis methods, supporting DMPK evaluations and onwards transition through clinical trials, are essential to their successful progression to market. Development of accurate and robust analytical quantitative methodologies for peptides brings inherent challenges in efficient mrm optimisation, non specific binding and assay sensitivity. This exclusive webinar will dive into the latest advancements in comprehensive LC‑MS/MS analytical workflows, resolving these challenges, and enabling efficient development of robust, sensitive large peptide LC‑MS/MS assays.
Join us as Samantha Ferries, Senior Applications Chemist at Waters Corporation, presents efficiency and performance benefit insights from her recent work in optimizing the LC-MS/MS quantification of Semaglutide in plasma.